Methods of treatment or prevention of acute brain or nerve injuries
One of the aspects of the invention is directed toward a method of treating or preventing acute brain or nerve injury in a subject, comprising administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiphen, to the subject in need thereof. Similarly, another aspect of the invention is directed toward a use of posiphen, or a pharmaceutically acceptable salt of posiphen, for the treatment or prevention of acute brain or nerve injury. Preferably, the posiphen in the method or use of the invention is posiphen tartrate.
1. A method of treating an acute brain or acute nerve injury in a human subject, consisting of administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiphen intravenously, intramuscularly, subcutaneously, intraperitoneally, topically, orally, sublingually or buccally, to a human subject prior to the human subject experiencing the acute brain or acute nerve injury in order to reduce nerve cell death, wherein the posiphen or pharmaceutically acceptable salt thereof is administered within about 3 days before an episode of the acute brain or nerve injury and is thereafter administered for at least 7 days, and wherein posiphen or a pharmaceutically acceptable salt of posiphen is administered once, twice, three times or four times within the first day, second day or third day before the episode of the acute brain or acute nerve injury occurs,
wherein the acute brain or acute nerve injury is traumatic brain injury.
2. The method according to claim 1 , wherein the episode of acute brain injury is associated with physical impact of the head.
3. The method according to claim 2 , wherein the pharmaceutically acceptable salt of posiphen is posiphen tartrate.
4. The method according to claim 1 , wherein posiphen or the pharmaceutically acceptable salt of posiphen is administered intravenously.
5. The method according to claim 1 , wherein posiphen is administered orally at a dose of 0.1 to 10 mg/kg body weight, or the pharmaceutically acceptable salt of posiphen is administered orally at a dose that is equivalent to a posiphen dose of 0.1 to 10 mg/kg body weight.
6. The method according to claim 4 , wherein posiphen is administered intravenously at a dose of 0.01 to 2 mg/kg body weight, or the pharmaceutically acceptable salt of posiphen is administered intravenously at a dose that is equivalent to a posiphen dose of 0.01 to 2 mg/kg body weight.
7. The method according to claim 1 , wherein posiphen or the pharmaceutically acceptable salt of posiphen is administered intramuscularly or intraperitoneally.